Global Candidiasis Drugs Market 2019-2023
The signs and symptoms of candidiasis are very broad, and they also
depend on the type of candidiasis infection. Therefore, to create
awareness about the disease and treatment options and avoid delay in
diagnosis, the CDC is providing information about candidiasis, and its
causes, risk factors, transmission, diagnosis, and treatment.
Furthermore, several organizations are providing free access to online
health information to prevent various diseases and minimize the effects
of ongoing health conditions, including candidiasis, Hence, the increase
in the number of organizations and institutes that create awareness
about candidiasis among people is expected to drive the growth of the
global candidiasis drugs market during the forecast period.
Global candidiasis drugs market: Advances in diagnosis of antifungal-resistant pathogens
Although the currently available antifungal drugs are killing various species of candidiasis, some fungi can develop the ability to defend these drugs and can cause serious bloodstream infections in hospitalized patients. Hence, advanced technologies where the system uses a technology called matrix-assisted laser desorption/ionization (MALDI-TOF) mass spectrometry, in combination with the reference organism database. In this technique, microorganisms, which are cultured from patient samples are ionized by the laser to produce a spectrum of microorganisms, which are matching with the spectrum of reference microorganism database to identify the microorganisms. Such technologies are expected to improve the diagnosis further in coming years, which support the market growth during the forecast period through early confirmation of the disease for the treatment.
Global candidiasis drugs market: Segmentation
analysis
This market research report segments the global candidiasis drugs market by type (azoles, echinocandins, other drugs) and geographical regions (North America, Europe, Asia, and ROW).
The North American region led the market in 2018, followed by North America, APAC, South America, and MEA respectively. However, during the forecast period, the APAC region is expected to register the highest incremental growth due to the rising awareness about diagnosis and management of invasive fungal infections.
Global candidiasis drugs market: Advances in diagnosis of antifungal-resistant pathogens
Although the currently available antifungal drugs are killing various species of candidiasis, some fungi can develop the ability to defend these drugs and can cause serious bloodstream infections in hospitalized patients. Hence, advanced technologies where the system uses a technology called matrix-assisted laser desorption/ionization (MALDI-TOF) mass spectrometry, in combination with the reference organism database. In this technique, microorganisms, which are cultured from patient samples are ionized by the laser to produce a spectrum of microorganisms, which are matching with the spectrum of reference microorganism database to identify the microorganisms. Such technologies are expected to improve the diagnosis further in coming years, which support the market growth during the forecast period through early confirmation of the disease for the treatment.
This market research report segments the global candidiasis drugs market by type (azoles, echinocandins, other drugs) and geographical regions (North America, Europe, Asia, and ROW).
The North American region led the market in 2018, followed by North America, APAC, South America, and MEA respectively. However, during the forecast period, the APAC region is expected to register the highest incremental growth due to the rising awareness about diagnosis and management of invasive fungal infections.
Comments
Post a Comment